Article Information
vol. 30 no. 160
PubMed
Published By
Print ISSN
Online ISSN
History
- Received February 25, 2021
- Accepted April 2, 2021
- Published online June 1, 2021.
Copyright & Usage
Copyright ©The authors 2021 This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
Author Information
- Saskia Bos1⇑,
- Laurens J. De Sadeleer2,3,
- Arno Vanstapel3,
- Hanne Beeckmans4,
- Annelore Sacreas3,
- Jonas Yserbyt1,3,
- Wim A. Wuyts1,3 and
- Robin Vos1,3
- 1Dept of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium
- 2Dept of Respiratory Diseases, Ziekenhuis Oost-Limburg, Genk, Belgium
- 3Dept of CHROMETA, Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), KU Leuven, Leuven, Belgium
- 4Dept of Internal Medicine, University Hospitals Leuven, Leuven, Belgium
- Corresponding author: Saskia Bos (saskia.bos{at}uzleuven.be)
Article usage
Altmetrics
Vol 30 Issue 160
Table of Contents
Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review
Jump To
- Article
- Abstract
- Abstract
- Introduction
- Pirfenidone and nintedanib: two key antifibrotic drugs
- Antifibrotics in IPF
- Antifibrotics in non-IPF progressive fibrosing ILD
- Antifibrotics in ILD patients referred for LTx
- Mechanisms of antifibrotics on the pathophysiological processes after LTx and in CLAD development
- Antifibrotics in CLAD phenotype BOS
- Antifibrotics in CLAD phenotype RAS
- Future areas of interest
- Conclusion
- Footnotes
- References
- Figures & Data
- Info & Metrics